233 related articles for article (PubMed ID: 25201298)
1. Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method.
Morakul B; Suksiriworapong J; Chomnawang MT; Langguth P; Junyaprasert VB
Eur J Pharm Biopharm; 2014 Nov; 88(3):886-96. PubMed ID: 25201298
[TBL] [Abstract][Full Text] [Related]
2. Precipitation-lyophilization-homogenization (PLH) for preparation of clarithromycin nanocrystals: influencing factors on physicochemical properties and stability.
Morakul B; Suksiriworapong J; Leanpolchareanchai J; Junyaprasert VB
Int J Pharm; 2013 Nov; 457(1):187-96. PubMed ID: 24076396
[TBL] [Abstract][Full Text] [Related]
3. Impact of uncharged and charged stabilizers on in vitro drug performances of clarithromycin nanocrystals.
Soisuwan S; Teeranachaideekul V; Wongrakpanich A; Langguth P; Junyaprasert VB
Eur J Pharm Biopharm; 2019 Apr; 137():68-76. PubMed ID: 30769087
[TBL] [Abstract][Full Text] [Related]
4. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability.
Ige PP; Baria RK; Gattani SG
Colloids Surf B Biointerfaces; 2013 Aug; 108():366-73. PubMed ID: 23602990
[TBL] [Abstract][Full Text] [Related]
5. Comparing various techniques to produce micro/nanoparticles for enhancing the dissolution of celecoxib containing PVP.
Homayouni A; Sadeghi F; Varshosaz J; Garekani HA; Nokhodchi A
Eur J Pharm Biopharm; 2014 Sep; 88(1):261-74. PubMed ID: 24952357
[TBL] [Abstract][Full Text] [Related]
6. Characterization and evaluation in vivo of baicalin-nanocrystals prepared by an ultrasonic-homogenization-fluid bed drying method.
Shi-Ying J; Jin H; Shi-Xiao J; Qing-Yuan L; Jin-Xia B; Chen HG; Rui-Sheng L; Wei W; Hai-Long Y
Chin J Nat Med; 2014 Jan; 12(1):71-80. PubMed ID: 24484600
[TBL] [Abstract][Full Text] [Related]
7. Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation.
Jiang T; Han N; Zhao B; Xie Y; Wang S
Drug Dev Ind Pharm; 2012 Oct; 38(10):1230-9. PubMed ID: 22229827
[TBL] [Abstract][Full Text] [Related]
8. Design, Optimization, and Evaluation of Lurasidone Hydrochloride Nanocrystals.
Shah S; Parmar B; Soniwala M; Chavda J
AAPS PharmSciTech; 2016 Oct; 17(5):1150-8. PubMed ID: 26586537
[TBL] [Abstract][Full Text] [Related]
9. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets.
Lai F; Pini E; Angioni G; Manca ML; Perricci J; Sinico C; Fadda AM
Eur J Pharm Biopharm; 2011 Nov; 79(3):552-8. PubMed ID: 21820052
[TBL] [Abstract][Full Text] [Related]
10. Investigation into physical-chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles.
Shahbazi Niaz M; Traini D; Young PM; Ghadiri M; Rohanizadeh R
Pharm Dev Technol; 2014 Dec; 19(8):911-21. PubMed ID: 24093825
[TBL] [Abstract][Full Text] [Related]
11. Development of an oral rutin nanocrystal formulation.
Mauludin R; Müller RH; Keck CM
Int J Pharm; 2009 Mar; 370(1-2):202-9. PubMed ID: 19114097
[TBL] [Abstract][Full Text] [Related]
12. Aceclofenac nanocrystals with enhanced in vitro, in vivo performance: formulation optimization, characterization, analgesic and acute toxicity studies.
Rahim H; Sadiq A; Khan S; Khan MA; Shah SMH; Hussain Z; Ullah R; Shahat AA; Ibrahim K
Drug Des Devel Ther; 2017; 11():2443-2452. PubMed ID: 28860715
[TBL] [Abstract][Full Text] [Related]
13. Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin.
Kristin F; René H; Boontida M; Buraphacheep JV; Maximilian A; Johanna M; Peter L
Eur J Pharm Sci; 2017 Apr; 101():211-219. PubMed ID: 28179133
[TBL] [Abstract][Full Text] [Related]
14. A novel high-pressure precipitation tandem homogenization technology for drug nanocrystals production - a case study with ursodeoxycholic acid.
Li Y; Wang Y; Yue PF; Hu PY; Wu ZF; Yang M; Yuan HL
Pharm Dev Technol; 2014 Sep; 19(6):662-70. PubMed ID: 23869484
[TBL] [Abstract][Full Text] [Related]
15. Dissolution study of nanocrystal powders of a poorly soluble drug by UV imaging and channel flow methods.
Sarnes A; Østergaard J; Jensen SS; Aaltonen J; Rantanen J; Hirvonen J; Peltonen L
Eur J Pharm Sci; 2013 Nov; 50(3-4):511-9. PubMed ID: 23999036
[TBL] [Abstract][Full Text] [Related]
16. Enhanced oral bioavailability of glycyrrhetinic acid via nanocrystal formulation.
Lei Y; Kong Y; Sui H; Feng J; Zhu R; Wang W
Drug Deliv Transl Res; 2016 Oct; 6(5):519-25. PubMed ID: 27206446
[TBL] [Abstract][Full Text] [Related]
17. Hyperoside nanocrystals for HBV treatment: process optimization, in vitro and in vivo evaluation.
Shen B; Wu N; Shen C; Zhang F; Wu Y; Xu P; Zhang L; Wu W; Lu Y; Han J; Wang Y; Yuan H
Drug Dev Ind Pharm; 2016 Nov; 42(11):1772-81. PubMed ID: 27032257
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation.
He Y; Xia DN; Li QX; Tao JS; Gan Y; Wang C
Acta Pharmacol Sin; 2015 Sep; 36(9):1151-60. PubMed ID: 26256404
[TBL] [Abstract][Full Text] [Related]
19. Kinetic solubility and dissolution velocity of rutin nanocrystals.
Mauludin R; Müller RH; Keck CM
Eur J Pharm Sci; 2009 Mar; 36(4-5):502-10. PubMed ID: 19130880
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical and pharmacokinetic characteristics of different types of fenofibrate nanocrystals prepared by different bottom-up approaches.
Zhang H; Meng Y; Wang X; Dai W; Wang X; Zhang Q
Drug Deliv; 2014 Dec; 21(8):588-94. PubMed ID: 24320001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
